AKTX today
$6.80+$0.29 (+4.45%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $15.50
Key levels
Resistance$9.83
Resistance$7.58
Support$6.51
Support$5.01
Latest news & SEC filings
EarningsAkari Therapeutics Posts Q3 2026 Results, Updates Clinical Work
SEC FilingAkari Therapeutics Plc filed a report on a major company event (Form 8-K)
All AKTX news →About Akari Therapeutics
Akari Therapeutics is a clinical-stage biopharmaceutical firm focused on creating antibody-drug conjugates for cancer treatment. Its main technology uses a proprietary payload called PH1 that interferes with RNA splicing inside tumor cells, causing cell death and stimulating an immune response. The company's lead candidates include AKTX-101, aimed at the Trop-2 receptor, and AKTX-102, aimed at CEACAM5, for solid tumors affecting organs such as the lungs, breasts, bladder, pancreas, and colon.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
Akari Therapeutics Plc (AKTX)
What Is the Price Target for AKTX?
SEPT Low Target
$30.00
SEPT Mid Target
$30.00
SEPT High Target
$30.00
Analyst Consensus
$30.00
Is AKTX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AKTX.
Start Free Trial →Is AKTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$30.00
7
Moat Score
NONE
4/9
Piotroski Score
17108.6
Altman Z-Score
What Is Smart Money Doing with AKTX?
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Patel Sandip I | director | Buy | 3,866 | $1.55 | Oct 14, 2026 |
| Patel Sandip I | director | Buy | 6,186 | $2.47 | Oct 14, 2026 |
| Bazemore Robert B | director | Buy | 773 | $0.31 | Oct 14, 2026 |
| Bazemore Robert B | director | Buy | 3,093 | $1.24 | Oct 14, 2026 |
| Gaslightwala Abizer | director officer | Buy | 19,333 | $7.73 | Oct 14, 2026 |
| Gaslightwala Abizer | director officer | Buy | 7,733 | $3.09 | Oct 14, 2026 |
| Huh Hoyoung | director 10% owner | Buy | 6,160 | $49K | Oct 5, 2026 |
| Prudo-Chlebosz Raymond | director | Buy | 3,240 | $26K | Oct 5, 2026 |
| Patel Sandip I | director | Buy | 4,313 | $34K | Oct 5, 2026 |
| Bazemore Robert B | director | Buy | 4,677 | $37K | Oct 5, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AKTX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for AKTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AKTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:10:32 | $7.54 | 2,000 | $$15K | SELL |
| 21:14:43 | $7.31 | 1,000 | $$7K | SELL |
| 14:47:35 | $7.89 | 3,400 | $$27K | BUY |
| 16:24:03 | $7.75 | 1,079 | $$8K | SELL |
| 16:03:58 | $7.42 | 2,500 | $$19K | SELL |
5 dark pool trades shown · $$76K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Akari Therapeutics Plc (AKTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AKTX — frequently asked questions
What is AKTX stock price today?
Akari Therapeutics Plc (AKTX) is at $6.80, up 4.45% (+$0.29) at the Nov 13, 2026 close.
Why is AKTX stock moving today?
Latest AKTX news — Nov 13, 2026: Akari Therapeutics Posts Q3 2026 Results, Updates Clinical Work · Nov 12, 2026: Akari Therapeutics Plc filed a report on a major company event (Form 8-K)
What is the AKTX price target?
The average analyst price target for AKTX is $30.00, ranging from $30 to $30, based on 1 analysts. Latest: Maxim Group upgrade on Jul 20, 2026.
What do analysts rate AKTX?
Analyst ratings for AKTX: 1 Buy, 0 Hold, 1 Sell — consensus Hold.
Did AKTX beat earnings?
AKTX last reported on Aug 13, 2026: EPS -$272.00 vs -$1.04 expected — a miss of 26053.8%.
Does AKTX pay a dividend?
AKTX does not currently pay a dividend.
What are AKTX support and resistance levels?
Support: $6.51, $5.01, $3.02. Resistance: $7.58, $9.83, $10.97.
What are insiders doing with AKTX?
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.
What is the latest news on AKTX?
Nov 13, 2026: Akari Therapeutics Posts Q3 2026 Results, Updates Clinical Work · Nov 12, 2026: Akari Therapeutics Plc filed a report on a major company event (Form 8-K)